Pamicell Rises 5.07% Amid COVID-19 (Remdesivir) Theme Uptrend

On the 18th, the COVID-19 (Remdesivir) theme rose by 3.31% compared to the previous day, showing strength, while Pharmicell, a related stock attracting attention, surged by 5.07% compared to the previous day. Pharmicell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.

[Graph] Major stock price changes in the COVID-19 (Remdesivir) theme

According to provisional data compiled at 11:27, foreign investors have been buying 64,000 shares of Pharmicell, indicating a large net purchase by foreigners.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Pharmicell ranked 2nd out of 4 stocks in the quant financial ranking by exceeding the theme's average scores in growth, stability, and profitability. This can be interpreted as Pharmicell having a relatively high investment attractiveness compared to other stocks in the theme from a financial perspective.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.